EQUITY, SHARE-BASED COMPENSATION AND WARRANTS | NOT E 10. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS A summary of equity activity for the three months ended March 31, 2019 and March 31, 2018, follows (in thousands, except share amounts). Shares Preferred Series G Common Preferred Stock Common Stock Accumulated Deficit Equity Balance, December 31, 2018 405 29,098,207 $ 201 $ 296,739 $ (273,229 ) $ 23,711 Proceeds from sale of common stock and pre-funded warrant, net of costs - 3,046,668 - 11,593 - 11,593 Common stock awards under equity incentive plans - 36,881 - 364 - 364 Exercise of common stock warrants - 600,000 - 1,980 - 1,980 Conversion of preferred stock into common stock (180 ) 170,818 (89 ) 89 - - Exercise of common stock options - 77,078 - 60 - 60 Other - - - 28 - 28 Net loss - - - - (3,227 ) (3,227 ) Balance, March 31, 2019 225 33,029,652 $ 112 $ 310,853 $ (276,456 ) $ 34,509 Shares Preferred Series G Common Preferred Stock Common Stock Accumulated Deficit Equity Balance, December 31, 2017 630 18,046,731 $ 313 $ 279,548 $ (265,128 ) $ 14,733 Common stock awards under equity incentive plans - 78,377 - 245 - 245 Exercise of common stock warrants - 1,827,999 - 1,755 - 1,755 Other - - - 75 - 75 Net loss - - - - (1,913 ) (1,913 ) Balance, March 31, 2018 630 19,953,107 $ 313 $ 281,623 $ (267,041 ) $ 14,895 On March 8, 2019, we issued and sold 3,046,668 shares of common stock for $3.00 per share and a pre-funded warrant exercisable into 1,003,344 shares of common stock for $2.99 per share, in a private placement. The warrant has an exercise price of $0.01 per share and is immediately exercisable, however the current holder must obtain approval from our shareholders to exercise the warrant to the extent such exercise would result in the shareholder owning in excess of 19.99% of our common shares outstanding. The warrant expires in March 2029. We determined the pre-funded warrant qualifies for equity accounting. The net proceeds from the offering of $11.6 million, after deducting commissions and other cash offering expenses of $0.5 million, are recorded in equity. We determined the exercise price of the warrant is nominal and, as such, have considered the 1,003,344 shares underlying the warrant to be outstanding effective March 8, 2019, for the purposes of calculating basic EPS. During the three months ended March 31, 2019, we also issued: • 30,887 shares of common stock to employees with a fair value at issuance of $3.22 per share. • 5,994 shares of common stock to a consultant with an average fair valuer at issuance of $3.48 per share. • 600,000 shares of common stock upon exercise of warrants at an exercise price of $3.30 per share. The exercised warrants had expiration dates in April 2019. • 170,818 shares of common stock upon conversion of 180 shares of Series G preferred stock. We reclassified the $0.1 million carrying value of the related preferred stock to common stock. • 77,078 shares of common stock upon exercise of options at a weighted average exercise price of $0.78 per share. • options to employees and a consultant for the purchase of up to 188,662 shares of common stock at an average exercise price of $3.25 per share and an average grant date fair value of $2.05 per share. The options vest and become exercisable in four equal annual installments beginning in January and February 2020. During the three months ended March 31, 2019, warrants for the issuance of up to 950,614 shares of common stock at an exercise price of $5.25 per share expired. During the three months ended March 31, 2019, a vendor earned and we expensed the value of 9,148 shares, previously issued and held in escrow. These shares were valued at $2.92 per share, the fair value of the shares on January 1, 2019, when we adopted ASU 2018-07. During the three months ended March 31, 2018, we issued: • 50,469 shares of common stock to employees with an average fair value at issuance of $1.38 per share. • 27,908 shares of common stock to a consultant with an average fair value at issuance of $1.42 per share. • 1,827,999 shares of common stock when warrant holders exercised warrants at an exercise price of $0.96 per share. • warrants for the purchase of up to 315,000 shares of common stock, at a weighted average exercise price of $4.73 per share and a weighted average term of 2.4 years. We recognized $0.1 million of expense for these issuances. • options to employees for the purchase of up to 278,873 shares of common stock at an exercise price of $1.42 and a grant date fair value of $0.97 per share. The options vest and become exercisable in four equal annual installments beginning in January 2019. During the three months ended March 31, 2018, a vendor earned and we expensed the value of 9,824 shares, previously issued and held in escrow. The shares were valued at the $1.57 per share fair value of the shares when earned, under the guidance for nonemployee awards in effect in 2018, prior to our adoption of ASU 2018-07. |